OTTAWA, Nov. 19 /PRNewswire/ - TrialStat Corporation, the industry's firstclinical data solutions on demand company, today announced innovative newfeatures that further enhance the performance, reporting capabilities and easeof use for ClinicalAnalytics 4.0(TM), the company's on demand electronic datacapture (EDC) platform. Building on EDC deployment times that are nearly twiceas fast as the industry average, ClinicalAnalytics 4.0 (CA 4.0) now offerscontract research organizations (CROs) and biopharma companies easy-to-use andsophisticated graphical reporting tools, automated post data entry validationand optimized study management functionality through its secure browserinterface. As a result, customers can further accelerate the deployment,management and analysis of their clinical research data.
"We believe that the latest version of CA 4.0 will change the way peoplethink about EDC," said Jonathan Barker, President and CEO, TrialStatCorporation. "Our customers have always enjoyed CA 4.0's industry-leadingdeployment times and intuitive interface. This new release takes CA 4.0 to ahigher level of performance and flexibility delivering a best-in-class ondemand solution at a very competitive price."
To learn more about CA 4.0's new features from Jonathan Barker, pleasevisit www.trialstat.com to download his Podcast.
TrialStat Corporation provides innovative clinical data solutions ondemand that optimize the collection and management of research to enablecustomers to accelerate the commercialization of new life science products. CA4.0 is a robust and scaleable Web-based EDC on demand platform used by leadingclinical research organizations. SRS 4.0(TM) automates systematic reviewsusing real-time collaboration and management tools, while ESRNexus(TM)(www.esrnexus.com) is the most comprehensive and free Web-based search enginefor evidence-based reference literature. More information about TrialStat isavailable at www.trialstat.com.
ClinicalAnalytics 4.0, SRS 4.0 and ESRNexus are registered trademarks of
TrialStat Corporation.Details of CA 4.0's new features include: Browser Configurable Aggregated Study Reporting - Building on CA 4.0's existing reporting suite, the new capabilities simplify the ability to isolate, retrieve and view complex data sets, including audit trail information with the click of a button. These enhancements enable users to easily evaluate and compare data from multiple study sources within a project. For example, study managers can easily build reports that display clinical values graphically, such as vital signs or laboratory data across different visits, to identify trends or anomalies. Integrated Post Data Entry (PDE) Validation - Integrated PDE automatically validates the accuracy of data across multiple forms and subjects based on a study's configuration and associated data validation rules. Integrated PDE also simplifies and accelerates the validation of data, as well as ensures that it is consistently captured. Users, for instance, can use integrated PDE to easily identify data anomalies and outliers by applying building rules for multiple forms that check ranges, states and values. This ability to run early validation of study data, rather than at the end of a study, can dramatically speed the time from Last Patient Last Visit (LPLV) to database lock. Study Management - Project configuration and management has been further optimized to include improved user permission interfaces, form level permissions and date time controls. These enhancements allow for greater control over study data and enhance the flexibility of study designs.